πŸ‡ΊπŸ‡Έ FDA
Patent

US 10716869

Radiolabeled macrocyclic EGFR inhibitor

granted A61KA61K51/0459A61P

Quick answer

US patent 10716869 (Radiolabeled macrocyclic EGFR inhibitor) held by Oncodesign SA expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oncodesign SA
Grant date
Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K51/0459, A61P, A61P35/00